They are used to build brain cells, keeping the cell walls flexible and enabling the neurons to sprout new connections and ...

Adenosine deaminase 2 deficiency (DADA2) is an inborn error of immunity leading to systemic vasculitis, haematological manifestations, immune deficiency and/or autoimmunity. We report the case of a 26 ...

Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...

View post: Strength Coaches Swear by an Intense Time-Saving Training Technique That Helps Consistent Lifters Spark New Muscle Growth Omega-3s support heart, brain, mood, inflammation, and joint health ...

There are two types of complement 3 glomerulopathy: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD often begins earlier in life and may progress more quickly. Both are linked to an ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. In general, the most common type of ...

MINNEAPOLIS — Severe nutritional deficiencies can mimic rheumatic disease and result in delayed diagnosis and unnecessary workups, as illustrated in a series of four cases presented at the American ...

In a phase 3 trial, oral ferric citrate effectively raised hemoglobin and improved iron parameters in Taiwanese patients with iron deficiency anemia over 16 weeks. Ferric citrate significantly ...

Health Nutrient deficiency linked to heart disease risk for millions, new study warns Global study finds 76% of people worldwide are lacking in omega-3 fatty acids By Kelly McGreal Fox News Published ...

Share on Pinterest According to research, most people may not be getting enough omega-3 fatty acids in their diet. Image Credit: Tanja Ivanova/Getty Images A new research review reports that most ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an FDA review in 2026. In the ...